The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
The production suspension impacts commercial and clinical trial supply
Subscribe To Our Newsletter & Stay Updated
